Haemonetics Corporation Q2 FY2026 earnings call

• Disciplined execution led to strong core product growth, margin expansion, and earnings conversion to cash. • Focus on NexSys, TEG, and VASCADE; gaining plasma share, reinforcing TEG leadership, and executing vascular closure initiatives. • Blood Management Technologies grew 12% Q2 and 13% YTD driven by TEG disposable utilization and heparinase neutralization cartridge. • Interventional Technologies declined due to esophageal cooling softness but saw progress with SavvyWire. • Plasma business strong with share gains, organic growth, and renewed confidence in plasma therapeutics market. • Blood Center benefited from divestiture of whole blood franchise, focusing on apheresis.

Hospital revenue was $146 million in Q2 and $285 million YTD, up 5% reported and 4% organic. Blood Management Technologies grew 12% Q2 and 13% YTD. Interventional Technologies declined 5% Q2 and 6% YTD. Vascular Closure grew 2% Q2 and 3% YTD. Plasma revenue was $125 million Q2 and $255 million YTD, down 10% Q2 and 7% YTD; excluding CSL, organic grew 19% Q2 and 23% YTD. Blood Center revenue declined 18% Q2 and 21% YTD; organic grew 4% Q2 and 5% YTD.

• Raised full year adjusted EPS guidance to $4.80 to $5 per share. • Raised full year free cash flow guidance to $170M to $210M. • Revised full year revenue guidance from decline of 3%-6% to 1%-4%, organic growth ex CSL from 6%-9% to 7%-10%. • Updated hospital revenue growth guidance to 4%-7%. • Raised plasma revenue guidance to decline 4%-7% reported or 14%-17% organic ex CSL. • Raised Blood Center guidance to reported decline 17%-19%, organic flat.

• Factors in safe harbor statement and SEC filings that may cause results to differ. • Market cyclicality affecting plasma collections. • Competitive environment in Interventional Technologies, particularly in VASCADE.

Q: Rohin Patel of JPMorgan asks about plasma revenue drivers and collections growth.

A: Chris Simon responds about share gains, innovation, and collections volume growth.

Q: Marie Thibault of BTIG asks about IVT commercial efforts and green shoots.

A: Chris Simon details sales force changes, training, and trial progress.

Q: Joseph of Needham & Company asks about Blood Center growth drivers.

A: Chris Simon talks about divestiture of whole blood franchise and focus on apheresis.

Q: David Rescott of Baird asks about plasma collections and VASCADE competitiveness.

A: Chris Simon discusses sustainable plasma growth and VASCADE competitive strategies.

Q: Anja of BofA Securities asks about VASCADE sales force and Japan label expansion.

A: Chris Simon talks about sales force changes and Japan market dynamics.

Q: Anthony of Citi asks about HN cartridge launch in EMEA and Japan.

A: Chris Simon discusses market differences and long-term growth potential.

Q: Andrew Cooper of Raymond James asks about VASCADE economics and Blood Management innovation.

A: Chris Simon explains VASCADE clinical benefits and Blood Management innovation pipeline.

Q: Michael Petusky of Barrington Research asks about Vascular Closure progress and share repurchase.

A: Chris Simon talks about Vascular Closure green shoots and James D'Arecca discusses share repurchase plans.